Dynamic visualization of RANKL and Th17-mediated osteoclast function

Journal of Clinical Investigation

Volumn 123, Issue 2, 2013, Pages 866-873

  Kikuta, Junichi ^a,b   Wada, Yoh ^a   Kowada, Toshiyuki ^a   Wang, Ze ^c   Sun Wada, Ge Hong ^a,f   Nishiyama, Issei ^a,b   Mizukami, Shin ^a   Maiya, Nobuhiko ^d   Yasuda, Hisataka ^e   Kumanogoh, Atsushi ^a   Kikuchi, Kazuya ^a   Germain, Ronald N ^c   Ishii, Masaru ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NIKON CORPORATION   (Japan)

^e Oriental Yeast Co Ltd   (Japan)

^f DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CELL COMMUNICATION; CELL FUNCTION; CELL MATURATION; CELL MOTILITY; CELL POPULATION; CONTROLLED STUDY; FLUORESCENCE IMAGING; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; MOUSE; MULTIPHOTON MICROSCOPY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TH17 CELL;

ANIMALS; BONE RESORPTION; CELL COMMUNICATION; CELL DIFFERENTIATION; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE, MULTIPHOTON; OSTEOCLASTS; RANK LIGAND; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TH17 CELLS; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84873329143     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65054     Document Type: Article

References (37)

1. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4(8):638-649.
2. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002;2(4):389-406.
3. Takahashi N, et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology. 1988;122(4):1373-1382.
4. Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest. 2005;115(2):200-208.
5. Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am. 2006;37(1):35-51.
6. Mazo IB, et al. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity. 2005;22(2):259-270.
7. Ishii M, et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature. 2009;458(7237):524-528.
8. Ishii M, Kikuta J, Shimazu Y, Meier-Schellersheim M, Germain RN. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med. 2010;207(13):2793-2798.
9. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science. 1989;245(4920):855-857.
10. Nakamura H, Moriyama Y, Futai M, Ozawa H. Immunohistochemical localization of vacuolar H (+)-ATPase in osteoclasts of rat tibiae. Arch Histol Cytol. 1994;57(5):535-539.
11. Toyomura T, Oka T, Yamaguchi C, Wada Y, Futai M. Three subunit a isoforms of mouse vacuolar H (+) - ATPase. Preferential expression of the a3 isoform during osteoclast differentiation. J Biol Chem. 2000;275(12):8760-8765.
12. Toyomura T, et al. From lysosomes to the plasma membrane: localization of vacuolar-type H+-ATPase with the a3 isoform during osteoclast differentiation. J Biol Chem. 2003;278(24):22023-22030.
13. Sun-Wada GH, Tabata H, Kawamura N, Aoyama M, Wada Y. Direct recruitment of H+-ATPase from lysosomes for phagosomal acidification. J Cell Sci. 2009;122(pt 14):2504-2513.
14. Nishi T, Forgac M. The vacuolar (H+)-ATPases - nature's most versatile proton pumps. Nat Rev Mol Cell Biol. 2002;3(2):94-103.
15. Frattini A, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet. 2000;25(3):343-346.
16. Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K. Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res. 2007;22(4):487-494.
17. Tomimori Y, et al. Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. J Bone Miner Res. 2009;24(7):1194-1205.
18. Soysa NS, et al. The pivotal role of the alternative NF-kappaB pathway in maintenance of basal bone homeostasis and osteoclastogenesis. J Bone Miner Res. 2010;25(4):809-818.
19. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep. 2003;1(2):45-52.
20. Russell RG, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209-257.
21. Kowada T, et al. In vivo fluorescence imaging of bone-resorbing osteoclasts. J Am Chem Soc. 2011;133(44):17772-17776.
22. Nakayama T, et al. Polarized osteoclasts put marks of tartrate-resistant acid phosphatase on dentin slices - a simple method for identifying polarized osteoclasts. Bone. 2011;49(6):1331-1339.
23. Burgess TL, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999;145(3):527-538.
24. Kong YY, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402(6759):304-309.
25. Takayanagi H, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 2000;408(6812):600- 605.
26. Sato K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673-2682.
27. Asselin-Labat ML, et al. Control of mammary stem cell function by steroid hormone signalling. Nature. 2010;465(7299):798-802.
28. Furuya Y, et al. Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts. J Biol Chem. 2011;286(42):37023-37031.
29. Simonet WS, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-319.
30. Parfitt AM, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2(6):595-610.
31. Matsumoto T, et al. Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis. Arthritis Rheum. 2011;63(12):3908-3917.
32. Kuroshima S, Go VA, Yamashita J. Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice. Endocrinology. 2012;153(1):17-28.
33. Adamopoulos IE, Bowman EP. Immune regulation of bone loss by Th17 cells. Arthritis Res Ther. 2008;10(5):225.
34. Peck A, Mellins ED. Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin Immunol. 2009;132(3):295-304.
35. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol. 2009;5(12):667-676.
36. Lee EC, et al. A highly efficient Escherichia colibased chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics. 2001;73(1):56-65.
37. Alworth SV, Watanabe H, Lee JS. Teachable, highcontent analytics for live-cell, phase contrast movies. J Biomol Screen. 2010;15(8):968-977.